In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 41 for your search:

Drug:  exemestane
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Aromatase Inhibitor Clinical Trial

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 40 to 70
Sponsor: NIGMS
Protocol IDs: 0412-14, UO1-GM61373-06, NCT00228956

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09 SEIN 09, NCT01127295

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11 SEIN 09, NCT01553903

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11SEIN12, NCT01612871

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: 0120070323, NCT00698971

Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: TENBC, NCT01648608

Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: ECOG-PACCT-1, PACCT-1, NCT00310180

Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Followed By Either Anastrozole, Letrozole, or Exemestane Versus Anastrozole, Letrozole, or Exemestane Alone in Postmenopausal Women With Resected Endocrine-Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: GIM-3-FATA, GIM3-FATA, EUDRACT-2006-004018-42, EU-20764, NCT00541086

Phase III Randomized Study of Fulvestrant With or Without Lapatinib Tosylate and/or Aromatase Inhibitor Therapy in Postmenopausal Women With Metastatic Breast Cancer That Progressed After Prior Aromatase Inhibitor Therapy

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GIM-GIM8-OVER, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194

10.

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: CDR0000635986, COL-MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, MNEMOSYNE, NCT00893061

11.

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: SHBCC0701, NCT00902954

12.

Phase III Randomized Study of Standard Adjuvant Endocrine Therapy With Versus Without Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive, and HER2-Negative Breast Cancer

Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S1007, S1007, NCT01272037

13.

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Arobase (GINECO-BR107), NCT01303679

14.

Phase III Randomized Study of Acupuncture Versus Sham Acupuncture Versus Waiting List for Joint Symptoms Related to Aromatase Inhibitors in Patients With Stage I-III Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Approved-not yet active
Age: Postmenopausal
Sponsor: NCI
Protocol IDs: SWOG-S1200, S1200, NCT01535066

15.

Phase III Randomized Study of Duloxetine Hydrochloride in Treating Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Early-Stage Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: Not specified
Sponsor: NCI
Protocol IDs: SWOG-S1202, S1202, NCT01598298

16.

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DETECT III, 2010-024238-46, NCT01619111

17.

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001JDE49, NCT01626222

18.

Phase II Randomized Study of Adjuvant Endocrine Therapy With Versus Without Everolimus in Patients With High-Risk, Hormone Receptor-Positive, and HER2/neu-Negative Breast Cancer

Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S1207, S1207, NCT01674140

19.

Phase I/II Randomized Pilot Study of Neoadjuvant Therapy Comprising Sunitinib Malate and Exemestane in Postmenopausal Women With Hormone Receptor-Positive and HER-2 Negative Primary Breast Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: ICO-SUT-EXE-08, SUT-EXE-08, PFIZER-ICO-SUT-EXE-08, NCT00931450

20.

Safety and Efficacy of AZD4547 in Combination With Exemestane Versus Exemestane Alone in ER+ Breast Cancer Patients

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D2610C00003, 2010-021220-10, NCT01202591

21.

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000595712, SINGAPORE-NCC0706, NCC0706, NCT00687648

22.

Exemestane or Docetaxel-cytoxan in Low Recurrence Score Cancers

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WCI1534-08, NCT00941330

23.

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MM-121-02-02-03 (ARD11588), NCT01151046

24.

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR018286, 212082BCA2001, 2011-000621-80, NCT01381874

25.

Study of Aspirin in the Exemestane to Adjuvant Treatment of Breast Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 50 to 80
Sponsor: Other
Protocol IDs: ChineseAMS CH-BC-011, NCT01431053

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®